Status:
UNKNOWN
Assessment of Efficacy of KAN-JANG® in Mild COVID-19
Lead Sponsor:
Swedish Herbal Institute AB
Collaborating Sponsors:
Tbilisi State Medical University
Phytomed AB
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The complexity of COVID-19 suggests a potential need for a range of therapies, including antiviral agents, immunostimulants, immunosuppressants, adaptogens, and anticoagulants. In this context, implem...
Detailed Description
Rationale. Pathogenesis and progression of COVID-19 is a multistep process, which requires correct therapeutic strategy on various steps of initiation of overall defense response to pathogen and its r...
Eligibility Criteria
Inclusion
- Laboratory confirmed (SARS-Cov-2 PCR-positive test) mild COVID-19 infection (in the last three days),
- COVID-19 patient in stable, moderate condition (i.e., not requiring Intensive Care Unit (ICU) admission).
- Subjects must be under observation or admitted to a controlled facility or hospital (home quarantine is not sufficient).
- Able to take medication alone
- Able to give informed consent.
Exclusion
- Pulmonary diseases
- Chronic pulmonary diseases
- Chronic rhinosinusitis
- Patient admitted already under invasive mechanical ventilation;
- The patient admitted with the severe acute respiratory syndrome and diagnosed with an etiologic agent other than Covid 19;
- Renal failure requiring dialysis or creatinine ≥ 2.0mg/dl;
- Tube feeding or parenteral nutrition.
- Respiratory decompensation requiring mechanical ventilation.
- Uncontrolled diabetes type 2.
- Hypertension stage 3,
- Autoimmune disease.
- Pregnant or lactating women.
- Patients are taking antibiotics for a reason other than COVID-19 at enrollment.
- Has a chronically weakened immune system (AIDS, lymphoma, chemo-radio- corticosteroid therapy, immunosuppressive pathology);
- Patients treated with chemo-radio-corticosteroid therapy in the last six months.
- Patients with active cancer.
- Taking immunosuppressive drugs (e.g., anti-rejection treatment after organ transplant);
- Already participating in another clinical trial;
- Has any other condition that would prevent safe participation in the study.
Key Trial Info
Start Date :
May 26 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2022
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT04847518
Start Date
May 26 2021
End Date
March 1 2022
Last Update
September 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First University Clinic of Tbilisi State Medical University
Tbilisi, Georgia, 0141